Medpace Holdings, Inc. Stock

Equities

MEDP

US58506Q1094

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:44:47 2024-04-24 pm EDT 5-day change 1st Jan Change
396.3 USD -2.66% Intraday chart for Medpace Holdings, Inc. +3.79% +29.49%
Sales 2024 * 2.18B Sales 2025 * 2.52B Capitalization 12.59B
Net income 2024 * 357M Net income 2025 * 414M EV / Sales 2024 * 5.46 x
Net cash position 2024 * 715M Net cash position 2025 * 1.04B EV / Sales 2025 * 4.58 x
P/E ratio 2024 *
36.7 x
P/E ratio 2025 *
31.4 x
Employees 5,800
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.65%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.27%
1 week+6.90%
Current month+1.16%
1 month+1.63%
3 months+37.86%
6 months+50.15%
Current year+33.37%
More quotes
1 week
355.79
Extreme 355.79
421.00
1 month
355.79
Extreme 355.79
421.00
Current year
277.72
Extreme 277.72
421.00
1 year
189.30
Extreme 189.3
421.00
3 years
126.95
Extreme 126.945
421.00
5 years
53.10
Extreme 53.1
421.00
10 years
21.76
Extreme 21.76
421.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 92-06-30
Director of Finance/CFO 49 18-10-31
President 49 07-09-30
Members of the board TitleAgeSince
Director/Board Member 72 18-08-12
Chief Executive Officer 67 92-06-30
Director/Board Member 64 18-08-12
More insiders
Date Price Change Volume
24-04-24 397.2 -2.46% 266 280
24-04-23 407.2 +8.21% 808,514
24-04-22 376.3 +1.15% 357,745
24-04-19 372 -0.62% 221,668
24-04-18 374.3 -2.12% 219,892

Delayed Quote Nasdaq, April 24, 2024 at 10:52 am EDT

More quotes
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
407.2 USD
Average target price
418.9 USD
Spread / Average Target
+2.89%
Consensus